MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

DA-1241 100mg showed statistically significant reductions in ALT levels at weeks 4 and 8 (p=0.0159 and p=0.0342, respectively) and a near statistically significant reduction (p=0.0506) at week 16 ...

DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering EffectPatients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, ...

Part 1 of this Phase 2a trial is exploring DA-1241, a novel G-Protein-Coupled Receptor 119, or GPR119, agonist compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in ...

"Importantly, DA-1241 was shown to be very well tolerated with mostly mild AEs and no drug related SAEs in the treatment groups. Based on this data, we continue to believe that the novel mechanism ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...